Clinical trials: Glial Tumor
Medulloblastoma
Radiation Therapy and Combination Chemotherapy for Medulloblastoma
This phase II trial is studying giving radiation therapy together with combination chemotherapy after surgery to see how well it works in treating children with newly diagnosed medulloblastoma.
- Trial name
- NCT02681705
- Testing
- Temozolomide, Craniospinal Radiation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Glioblastoma (GBM)
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
The goal of this clinical trial is to learn if a combined treatment approach can treat glioblastoma (GBM) with ventricular invasion or meningeal metastasis in adults.
- Trial name
- NCT07193654
- Testing
- Intrathecal injection of thiotepa, Stupp regimen (oral temozolomide), Radical radiotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Brain and Central Nervous System Tumors
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004937
- Testing
- acridine carboxamide
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High-Grade Gliomas
Bevacizumab and Irinotecan to Treat Brain Tumors
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. It has shown activity against human brain tumors in laboratory tests and human clinical trials.
- Trial name
- NCT00393094
- Testing
- Bevacizumab, Irinotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Glial Cell Tumors
hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors
PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included.
- Trial name
- PROGLIO (NCT05157594)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Jean Perrin
Malignant Glioma
D2C7-IT With Atezolizumab for Recurrent Gliomas
This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing cells, in patients with recurrent World Health…
- Trial name
- NCT04160494
- Testing
- D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Darell Bigner
Glioma
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy.
- Trial name
- NCT06818331
- Testing
- SMES+PTX, Paclitaxel, Specific mode electroacupuncture stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Glioblastoma, Gliosarcoma
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
This phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or…
- Trial name
- NCT04555577
- Testing
- Peposertib, Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Irinotecan in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent…
- Trial name
- NCT00003301
- Testing
- irinotecan hydrochloride
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma
GammaTile and Stupp in Newly Diagnosed GBM
In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival.
- Trial name
- GESTALT (NCT05342883)
- Testing
- Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- GT Medical Technologies, Inc.
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Glioma, Parietal Lobe Glioma
Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma
The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from…
- Conditions
- Glioma, Parietal Lobe Glioma, Visuspatial Deficit, Unilateral Spatial Neglect (USN)
- Trial name
- neGLIO (NCT07286929)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Glioma, Malignant
Glioblastoma and Individualized Therapies
The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years.
- Trial name
- NCT05356312
- Testing
- Vaccination
- Where
- Germany
- Sponsor
- Zentrum fur Humangenetik Tuebingen
Oligodendroglioma, Adult
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
RATIONALE: Current therapies for adult recurrent/progressive oligodendrogliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003472
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Burzynski Research Institute
Glioma, Glioblastoma
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
In this study, the investigators propose to combine retifanlimab with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM).
- Trial name
- NCT03532295
- Testing
- Epacadostat, Bevacizumab, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Glioma, GBM
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).
- Trial name
- NCT06855628
- Testing
- [6,6-²H₂]-Glucose
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Glioblastoma Multiforme, Relapse
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide.
- Trial name
- NCT06356883
- Testing
- IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Université de Sherbrooke
Glioblastoma (GBM)
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
- Trial name
- NCT07244666
- Testing
- Metabolically Armed EGFRvIII CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Low Grade Glioma of Brain, Multiple Sclerosis
Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)
This study aim to ensure that the implementation of a paramedical screening program and counseling in sexual health of patients with neurological pathologies (low-grade gliomas and Multiple Sclerosis) improves their sexual health.
- Conditions
- Low Grade Glioma of Brain, Multiple Sclerosis, Sexual Dysfunctions
- Trial name
- NEUROSEX (NCT03154801)
- Testing
- Paramedical care
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Malignant Glioma
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
Malignant glioma are the most common and aggressive primary brain tumors in adults. Despite advances in multimodal treatment including surgery, radiation and chemotherapy, most patients have a dismal prognosis of 9-15 months…
- Trial name
- AVIRMA01-09 (NCT01144988)
- Testing
- Bevacizumab / Irinotecan
- Where
- 2 sites in Austria
- Volunteers
- 35 people
- Sponsor
- Medical University Innsbruck
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.